Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. - Wikidata - wikimedia - TriplyDB

Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.

Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.

http://www.wikidata.org/entity/Q34318993

about

Antigen-based immunotherapy for autoimmune disease: current status Islet inflammation: a unifying target for diabetes treatment?Type 1 diabetes Insulitis in human type 1 diabetes: a comparison between patients and animal models Toward beta cell replacement for diabetes Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity.Combined therapy with GABA and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating T-cell autoimmunity and promoting β-cell replication in newly diabetic NOD mice.In search of a surrogate: engineering human beta cell lines for therapy.Characteristics and determinants of partial remission in children with type 1 diabetes using the insulin-dose-adjusted A1C definition Restoration of the unfolded protein response in pancreatic β cells protects mice against type 1 diabetes.β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.Expression profiling pre-diabetic mice to uncover drugs with clinical application to type 1 diabetes.Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes Perinatal tolerance to proinsulin is sufficient to prevent autoimmune diabetes.Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes.Introduction to personalized medicine in diabetes mellitus.Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice.It's time to bring dendritic cell therapy to type 1 diabetes.Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.Concise review: pluripotent stem cell-based regenerative applications for failing β-cell function Developing a vaccine for Type 1 diabetes through targeting enteroviral infections.Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray.JDRF's vision and strategy for prevention of type 1 diabetes.Depletion of IL-2 receptor β-positive cells protects from diabetes in non-obese diabetic mice.Status of autoimmune diabetes 20-year after generation of BDC2.5-TCR transgenic non-obese diabetic mouse.Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice.Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration.Therapeutic targeting of B cells and T cells in autoimmune diabetes: is it a solution?Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.Optimizing Multiplexed Detections of Diabetes Antibodies via Quantitative Microfluidic Droplet Array.Loss of intra-islet heparan sulfate is a highly sensitive marker of type 1 diabetes progression in humans.[Insulitis in type 1 diabetes].Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes

P2860

Q26852915-0B4DC990-4CDA-4432-98DE-C7FC7FE06063 Q26860847-F27D63A9-3D86-4E22-AA3E-AC435025C107 Q27000491-886B69FB-F36C-4620-838C-3D685E917F88 Q27023712-FC3C05B1-62FF-41E5-9D3E-5F75E56A867A Q28083650-728917BD-00B6-4005-9B69-728BB0EA0FEA Q33916508-9F52B078-8FC2-47B5-9840-30B0AC1B9980 Q34077377-6E45E1C5-7D4C-42CC-AB85-8167F9CD0C1C Q34117681-66539514-D8EA-4FC7-8623-B12BCE0D3F0D Q34181376-7CDD05B4-5D75-4CFF-AFEB-E1A32E15493A Q34213205-EFDA2B78-44B6-43A4-949E-B48BF4755D00 Q35904021-4962C0F9-A350-4AD2-93A8-24A50BEDBE3B Q36022067-CB658DEC-316F-4CB1-AD98-9A27F96293E1 Q36186226-258A8AA1-5A16-4FDB-A7D2-EED6BC1112D0 Q36913132-E928B800-CA3C-4ED4-8983-F3509D53DB37 Q37088185-D6C0EDEE-1B35-4464-82A0-D5B140FF16B2 Q37277296-75AB6397-18C1-4343-9436-7A2F5FE2FF83 Q37478584-062F12CB-286B-44AC-9FB4-0C04043A1E1E Q37523745-02DA3B14-DAD6-46D7-9C46-A50E919562DF Q37638227-37F8A8FE-5377-4DB8-876A-0599C1788833 Q37670174-B491AF83-68AD-4306-BDBF-2EFFEAF1E505 Q38117282-3C488B29-4084-4975-B692-534AFB365B27 Q38117284-A5D721B7-2927-4FFA-8B1F-BCF86B19C72C Q38197390-64492673-2D58-43B7-8178-6672DD616FD1 Q38223233-919B7524-149B-43A8-B68B-E4E6DD760885 Q38365047-763E96B2-C017-4EAF-A481-C37B515189AF Q38895435-DFCFBA76-DCE4-480B-BF2A-FE67975F4E50 Q41070908-93F0D280-5BA2-407C-BAB0-0133BAA592C5 Q41782901-C414083A-7114-46BF-A778-45B0806018FF Q42183951-9C764B0F-D8E5-4510-8372-22EE252519F2 Q42737518-1A09881E-E150-41EC-BF55-9B37465B5B7B Q42869996-668D38BA-5629-4F85-8846-A421EF1D244F Q45929111-E6E68167-2FBB-4703-B8DE-2A353164F7AA Q47153962-FF60B2F2-0160-4B96-BB2E-82F609EBB09D Q50133247-90BE66D8-D251-4743-9D48-81EA7B9F57BF Q53112191-E38900A4-61D4-4C56-BC2A-D910C9C3821C Q58831436-30F51243-910B-46D3-9240-3EF1DD9708A6

P2860

Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials.

http://www.wikidata.org/entity/Q34318993

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@ast

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@en

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@nl

type

label

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@ast

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@en

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@nl

prefLabel

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@ast

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@en

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@nl

P1433

Q34318993-31B79847-5AE8-45EC-AB8C-A8423F7F169E

P1476

Q34318993-0D2AC67A-349E-4235-994C-15AD15C3E3DC

P2093

Q34318993-3B8DBF1C-649F-40C3-8529-AA854E66642A

Q34318993-99219902-064B-4B75-A3A9-8695E66D7720

Q34318993-D4836637-DA58-4CE1-B36D-F28D8E079E92

P275

Q34318993-1DAB79CD-AE5A-4ADF-B1AF-386FFB2403E9

P2860

Q34318993-00F44A6E-FDF4-417F-A84F-E5FD51530269

Q34318993-02D8756E-5955-4395-8B1C-28278C07C20F

Q34318993-05576A84-2521-43FC-BBA9-8BF2DEC4E379

Q34318993-10E5CC56-B17E-43DE-83D0-4B7D77F8B336

Q34318993-192D5445-CDD2-479C-88AC-2D364E1A7D28

Q34318993-1E2A9758-0E3F-4D66-A741-A0981FAEAFA0

Q34318993-1E9BC99F-712C-45ED-B64D-64BF5BB663CF

Q34318993-25D5C660-A19A-453A-A597-65A14C6B8597

Q34318993-2778ADDC-AE2D-4937-8936-8A7F325357D8

Q34318993-29F68605-EBEE-42D2-A4B2-84D473EF5FFB

P304

Q34318993-D5805772-0380-4D58-85FB-58270BB83535

P31

Q34318993-3029D7E0-83A2-4B75-AAFB-880592F39E30

Q34318993-41D3DF5A-B0AD-42F2-B40C-6BB0A92159F2

P356

Q34318993-883139FB-8FC2-40E4-955F-952BBA35CFCE

P407

Q34318993-D75B492D-CBAD-4A34-94F6-19F45B4F8634

P433

Q34318993-663155D6-3653-46C6-BD92-18960CB8018F

P478

Q34318993-030D04FA-04A4-4B4B-A5FC-904370E47AF6

P50

Q34318993-2E0D7539-16E0-4366-9BFC-F17BD99C3769

P5008

Q34318993-585EB4B4-16F6-4652-9D03-94FBB65C7E4C

P577

Q34318993-E1DF25A7-3966-483A-B3F5-31462D10D7C0

P5875

Q34318993-F56ADC21-34C5-45D0-B327-0EF081E5674F

P698

Q34318993-148BE92C-62F7-4777-BA99-4A287EBDCDE2

P921

Q34318993-E191B2D2-79F7-4022-929B-EB04766E381F

Q34318993-F493BEB3-BA8D-4F35-84BA-32103E7EB14D

P932

Q34318993-2E661430-927D-428D-9C9E-E1E4FEF03497

P356

P1433

P1476

Recent lessons learned from pr ...... diabetes immunotherapy trials.

@en

P2093

Mark A Atkinson

http://www.w3.org/2001/XMLSchema#string

Richard Insel

http://www.w3.org/2001/XMLSchema#string

Teodora P Staeva

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivatives

P2860

C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus

Genetics, pathogenesis and clinical interventions in type 1 diabetes

Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man.

The pancreas in human type 1 diabetes.

P304

9-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DB12-0562

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

Lucienne Chatenoud

P5008

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233964989

http://www.w3.org/2001/XMLSchema#string

P698

23258904

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3526042

http://www.w3.org/2001/XMLSchema#string